An adjuvant is a substance that is formulated as part of a vaccine to enhance its ability to induce protection against infection. Adjuvants are substances added to vaccines to enhance the immunogenicity of highly purified antigens that have insufficient immunostimulatory capabilities.
South America Vaccine Adjuvants Market Segments Size & Growth:
South America vaccine adjuvants market size is projected to reach approximately $XX million by the end of 2024 with a CAGR of close to XX% from $XX million in 2017 during the forecast timeline 2018-2024. Key parameters promoting the market growth include increasing use of recombinant subunit and synthetic vaccines, Unmet Vaccine market needs for certain diseases, technological innovations and Expanding government recommendations for immunisations. However, lack of scientific awareness of adjuvants, Funding/cost of developing a new adjuvant, strict regulatory factors, high toxicity adjuvants and side effects of adjuvants are thereby hampering the market growth.
South America Vaccine Adjuvants Market Segments Share:
The type which comprises Aluminium Salts categorises South America vaccine adjuvants market, Tensoactive Adjuvants, Adjuvant Emulsions, Bacteria derived Adjuvants, Liposome Adjuvants, Carbohydrate Adjuvants, among others. Among them, Adjuvant Emulsions holds the most significant share in the market. By Route of administration into oral, intradermal, and intranasal. Among them, intranasal segment holds the most significant share in the market. By the mechanism of action into active immunostimulants, carriers, and vehicle adjuvants. By Geography, Brazil is projected to dominate the market with the most significant share and the growth in the South America economies is mainly attributed because of huge profit margins and growth prospects.
South America Vaccine Adjuvants Market Trends:
- Leading global biotherapeutics company, CSL Limited, officially opened a new AUD$230 million advanced manufacturing facility at its CSL Behring site in Broadmeadows with the assistance of Victorian Minister for Industry and Employment, Ben Carroll, MP.
- Novavax, Inc. announced the Phase 3 trial of its RSV F protein recombinant nanoparticle vaccine (RSV F Vaccine) for infants via maternal immunization will continue.
- Agenus Inc., an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, announced a $230 million non-dilutive royalty transaction with HealthCare Royalty Partners (HCR).
South America Vaccine Adjuvants Market Research Report:
An executive summary condensing the whole report such that essential authority can rapidly twist up doubtlessly acquainted with brief overview and conclusion.
To have complete market analysis, industry value chain analysis, Porter’s Five Force Analysis, PESTLE, SWOT analysis, and Y-o-Y analysis were carried to understand the market more comprehensively.
Regional and global diversity is analysed with the major countries and the unions. Scrutinizing the revenue generation on Year-On-Year
Identifying DROC in the current market and their impact in altering the market dynamics.
Competitive landscape analysis to identify the mergers and acquisitions which will have a comparative financial study with significant competitors.
Expertise investment opportunities by an analyst to the individual and organisation to have a better foothold in the market.
The primary market players, such as
- MPV Technologies
- Avanti Polar Lipids
- Agenus, Inc.
- Invivogen
- SPI Pharma, Inc.
1. Introduction
1.1 Executive Summary
1.2 Market Definition
1.3 Scope of the Study
2. Research Methodology
2.1 Secondary Research
2.2 Primary Research
2.3 Analytic Tools and Model
2.4 Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5 Expert Validation
2.6 Study Timeline
3. Market Analysis
3.1 Industry Value Chain Analysis
3.2 Porter’s Five Analysis
3.2.1 Bargaining Power of Buyers
3.2.2 Bargaining Power of Suppliers
3.2.3 Threats of Substitutes
3.2.4 Threats of New Entrants
3.2.5 Industry Rivalry
3.3 PESTLE Analysis
3.3.1 Political
3.3.2 Economical
3.3.3 Social
3.3.4 Technological
3.3.5 Legal
3.3.6 Environmental
3.4 SWOT Analysis
3.4.1 Strengths
3.4.2 Weakness
3.4.3 Opportunities
3.4.4 Threats
3.5 Y-O-Y Analyses
4. Market Dynamics
4.1 Drivers
4.1.1 Expanding government recommendations for immunizations
4.1.2 Increasing use of recombinant subunit and synthetic vaccines
4.1.3 Unmet Vaccine market needs for certain diseases
4.1.4 Technological innovations
4.2 Restraints
4.2.1 lack of scientific awareness of adjuvants
4.2.2 Funding/cost of developing a new adjuvant
4.2.3 High toxicity adjuvants
4.2.4 Side effects of adjuvants
4.2.5 strict regulatory factors
4.3 Opportunities
4.3.1 Pandemic Diseases
4.3.2 Combination Adjuvants
4.4 Challenges
4.4.1 Identification of Adjuvants
5. South America Vaccine Adjuvants Market – By Type
5.1 Aluminium Salts
5.2 Tensoactive Adjuvants
5.3 Adjuvant Emulsions
5.4 Bacteria derived Adjuvants
5.5 Liposome Adjuvants
5.6 Carbohydrate Adjuvants
5.7 others
6. South America Vaccine Adjuvants Market – By route of administration
6.1 oral
6.2 intradermal
6.3 intranasal
7. South America Vaccine Adjuvants Market – By mechanism of action
7.1 active immunostimulants
7.2 carriers
7.3 vehicle adjuvants
8. South America Vaccine Adjuvants Market – By Country
8.1.Introduction
8.2.Brazil
8.3. Argentina
8.4. Chile
8.5 Rest of South America
9. Company Profiles
9.1 OZ Biosciences
9.2 CSL Limited
9.3 SPI Pharma Inc.
9.4 Invivogen
9.5 Agenus, Inc.
9.6 Seppic
9.7 Brenntag Biosector
9.8 Novavax Inc.
9.9 Avanti Polar Lipids
9.10 MPV Technologies
10. South America Vaccine Adjuvants Market – Competitive Landscape
10.1 Market Share Analysis
10.2 Strategies Adopted by top companies
10.3 Mergers, Acquisitions, Collaborations & Agreements
11. Market Insights
11.1 Insights of Industry Experts
11.2 Investment Opportunities
11.3 Analyst Opinion
12. Appendix
12.1 List of Tables
12.2 List of Figures
